Ginelle C. Gellert, Ph.D. - Publications
Affiliations: | 2003 | University of North Texas Health Science Center at Fort Worth |
Area:
Immunology, Cell BiologyYear | Citation | Score | |||
---|---|---|---|---|---|
2009 | Yoon H, Kim DJ, Ahn EH, Gellert GC, Shay JW, Ahn CH, Lee YB. Antitumor activity of a novel antisense oligonucleotide against Akt1. Journal of Cellular Biochemistry. 108: 832-8. PMID 19693774 DOI: 10.1002/Jcb.22311 | 0.368 | |||
2006 | Gellert GC, Dikmen ZG, Wright WE, Gryaznov S, Shay JW. Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer. Breast Cancer Research and Treatment. 96: 73-81. PMID 16319992 DOI: 10.1007/S10549-005-9043-5 | 0.331 | |||
2005 | Herbert BS, Gellert GC, Hochreiter A, Pongracz K, Wright WE, Zielinska D, Chin AC, Harley CB, Shay JW, Gryaznov SM. Lipid modification of GRN163, an N3'-->P5' thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene. 24: 5262-8. PMID 15940257 DOI: 10.1038/Sj.Onc.1208760 | 0.342 | |||
2004 | Gellert GC, Goldfarb RH, Kitson RP. Physical association of uPAR with the alphaV integrin on the surface of human NK cells. Biochemical and Biophysical Research Communications. 315: 1025-32. PMID 14985115 DOI: 10.1016/J.Bbrc.2004.01.163 | 0.449 | |||
2003 | Gellert GC, Kitson RP, Goldfarb RH. Urokinase-type plasminogen activator receptor crosslinking in an NK cell line increases integrin surface expression by the MAP kinase/ERK 1/2 signaling pathway. Journal of Cellular Biochemistry. 89: 279-88. PMID 12704791 DOI: 10.1002/Jcb.10512 | 0.448 | |||
Show low-probability matches. |